Impact of Pharmacovigilance Based on PCNE Classification System on Treatment Outcomes,DRPs in Patients with Diabetic Nephropathy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的:观察基于欧洲药学监护联盟(pharmaceutical care network europe,PCNE)分类系统的药学监护对糖尿病肾病(diabetic nephropathy,DN)患者治疗效果及药物相关问题(drug-related problems,DRPs)的影响.方法:选取2021年5月—2022年5月医院收治的DN患者120例,经Excel产生随机序列号分为对照组、干预组,各60例.对照组按照医嘱用药,不进行药学监护,干预组通过PCNE系统进行药学监护.比较干预前、后两组临床指标及用药依从性;比较两组治疗效果及DRPs.结果:干预后两组空腹血糖(FBG)、收缩压、舒张压、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、血尿酸(SUA)、24 h尿蛋白定量均降低(P<0.05),干预组均低于对照组,两组高密度脂蛋白(HDL-C)、Morisky依从性量表(MMAS-8)评分均升高,干预组均高于对照组.干预组治疗效果等级分布及总有效率均高于对照组,DRPs发生率低于对照组.结论:基于PCNE分类系统的药学监护可改善DN患者治疗效果,提高患者用药依从性,减少DRPs.
Objective To observe the effects of pharmaceutical care based on the Pharmaceutical Care Network Europe(PCNE)classification system on the treatment outcomes and drug-related problems(DRPs)of patients with diabetic neph-ropathy(DN).Methods A total of 120 patients with DN admitted to the hospital from May 2021 to May 2022 were selected and divided into control group and intervention group with 60 cases each by random serial numbers generated by Excel.The control group received medication according to the doctor's orders,without pharmaceutical care,and the intervention group received pharmaceutical care through the PCNE system.The clinical indicators and medication adherence were compared.The treatment outcomes and DRPs of the two groups were compared.Results After the intervention,the fasting blood glucose(FBG),systo-lic blood pressure,diastolic blood pressure,triglyceride(TG),total cholesterol(TC),low-density lipoprotein(LDL-C),serum uric acid(SUA),and 24 h urine protein quantification of the two groups were decreased,and which of the intervention group were lower than those of the control group.The high-density lipoprotein(HDL-C)and Morisky Medication Adherence Scale(MMAS-8)scores of the two groups were increased,and which of the intervention group were higher than those of the control group.The distribution of treatment outcome levels and the total effective rate of the intervention group were higher than those of the control group,but the incidence of DRPs was lower.Conclusion Pharmaceutical care based on the PCNE classification system can improve the treatment outcomes of DN patients,increase their medication adherence,and reduce DRPs.
diabetic nephropathypharmaceutical care network europepharmaceutical caretreatment outcomesdrug-related problems
万方数据
